Pharmacotherapy of Child and Adolescent Psychiatric Disorders: Rosenberg/Pharmacotherapy of Child and Adolescent Psychiatric Disorders

This book fulfils an urgent need for an updated text on pediatric psychopharmacology. It takes a unique approach in discussing recent findings within the context of current issues, including economic and political ones. The book covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, e.g, schizophrenia or bipolar disorder, but who are deemed to be at high risk. This is an active area of debate: such children are being treated in certain centers, while others reject this completely. The book addresses the antidepressant controversy, the placebo response and unique strategies for delineating this, and ways to optimize the differential between active medication and placebo. It reviews the impact of recent American Heart Association guidelines for monitoring children on stimulants and other psychotropics. It adheres closely to DSM-IV diagnostic criteria throughout. The book describes the use of newly approved drugs such as Lexapro for treating adolescent depression and the novel compound Intuniv. It covers the TADS and CAMS studies, which evaluated the use of SSRIs alone and in combination with cognitive behavioral therapy for adolescent depression. Other topics include treatment of bipolar disorders, the increasing popularity of generic equivalents, combination pharmacotherapy and the potential dangers of psychotropic medications. Third edition of the first ever book published on pediatric psychopharmacology from renowned editors. Incorporates current developments with regard to SSRIs, their indications and their safety issues, including possible associated suicidal behavior. Addresses concerns about cardiovascular side effects of the new stimulant medications available, and compares to other FDA-approved medications for ADHD. Features many tables, figures and pictorials, making it highly accessible and reader friendly. Content: Chapter 1 Historical Perspectives on Child and Adolescent Psychopharmacology (pages 1–5): Samuel Gershon Chapter 2 Pharmacoepidemiology of Psychotropic Medications in Youth (pages 7–23): Daniel J. Safer and Julie Magno Zito Chapter 3 Off?Label Prescribing of Drugs in Child and Adolescent Psychiatry (pages 25–38): C. Lindsay Devane Chapter 4 The Use of Generic Drugs in Pediatric Psychopharmacology (pages 39–50): Richard I. Shader and Christopher?Paul Milne Chapter 5 Psychoactive Drug Use in Children: Basic Concepts in Clinical Pharmacology (pages 51–63): David J. Edwards Chapter 6 Psychostimulants (pages 65–104): Steven R. Pliszka Chapter 7 Tricyclic Antidepressants and Monoamine Oxidase Inhibitors for the Treatment of Child and Adolescent Psychiatric Disorders (pages 105–129): Charlotte M. Heleniak, Tejal Kaur, Kareem D. Ghalib and Moira A. Rynn Chapter 8 Selective Serotonin Reuptake Inhibitors (SSRIs) (pages 131–154): Dara Sakolsky and Boris Birmaher Chapter 9 Novel (Atypical) Antidepressants (pages 155–179): Heidi R. Bruty, Graham J. Emslie and Paul Croarkin Chapter 10 Antipsychotic Agents (pages 181–219): Brieana M. Rowles, John L. Hertzer and Robert L. Findling Chapter 11 Lithium (pages 221–259): Garrett M. Sparks and David A. Axelson Chapter 12 Anticonvulsants Used in Child and Adolescent Psychiatric Disorders (pages 261–299): Mani Pavuluri and Tushita Mayanil Chapter 13 Anxiolytics (pages 301–340): Barbara J. Coffey and Amanda L. Zwilling Chapter 14 Adrenergic Agents in Child and Adolescent Psychiatry (pages 341–364): Lawrence David Scahill Chapter 15 Atypical Psychopharmacologic Strategies (pages 365–397): Jess Shatkin and Aron Janssen Chapter 16 Psychopharmacology in Preschool Children (pages 399–420): Mini Tandon and Joan Luby Chapter 17 Combination Pharmacotherapy for Psychiatric Disorders in Children and Adolescents (pages 421–438): Gagan Joshi and Anna M. Georgiopoulos « This book fulfils an urgent need for an updated text on pediatric psychopharmacology. It takes a unique approach in discussing recent findings within the context of current issues, including economic and political ones. The book covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, e.g, schizophrenia or bipolar disorder, but who are deemed to be at high risk. This is an active area of debate: such children are being treated in certain centers, while others reject this completely. The book addresses the antidepressant controversy, the placebo response and unique strategies for delineating this, and ways to optimize the differential between active medication and placebo. It reviews the impact of recent American Heart Association guidelines for monitoring children on stimulants and other psychotropics. It adheres closely to DSM-IV diagnostic criteria throughout. The book describes the use of newly approved drugs such as Lexapro for treating adolescent depression and the novel compound Intuniv. It covers the TADS and CAMS studies, which evaluated the use of SSRIs alone and in combination with cognitive behavioral therapy for adolescent depression. Other topics include treatment of bipolar disorders, the increasing popularity of generic equivalents, combination pharmacotherapy and the potential dangers of psychotropic medications. Third edition of the first ever book published on pediatric psychopharmacology from renowned editors. Incorporates current developments with regard to SSRIs, their indications and their safety issues, including possible associated suicidal behavior. Addresses concerns about cardiovascular side effects of the new stimulant medications available, and compares to other FDA-approved medications for ADHD. Features many tables, figures and pictorials, making it highly accessible and reader friendly. »-- Résumé de l'éditeur Focusing on pediatric psychopharmacology, this title covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, such as schizophrenia or bipolar disorder, but who are deemed to be at high risk. It addresses concerns about cardiovascular side effects of the stimulant medications available. David Rosenberg MD, Miriam L. Hamburger Endowed Chair of Child Psychiatry and Professor & Chief of Child Psychiatry and Psychology at Wayne State University and the Children's Hospital of Michigan, Detroit, MI, USA Samuel Gershon MD, Emeritus Professor of Psychiatry, University of Pittsburgh, PA, USA